Table of contents
- Manufacture, marketing and sale
- ATMP trade organisations call for GMO exemption in EU
- Commission publishes plan for Regulation (EU) 2017/746, the IVDR
- PMCPA announces consultation of amendments to 2021 ABPI Code template
- MDCG publishes guidance in implant cards
- FAQs published on European Medical Device Nomenclature
- MDCG explains how IMDRF N48 guidance applies to MDR and IVDR
- Research and development
- Therapeutics and Vaccines Clinical Trials Charter agreed by G7 health ministers
- Further £1m pledged to develop treatments for antibiotic-resistant infections
More sections of this document available when you sign-in to Lexis+ or register for a free trial.
Article summary
This week's edition of Life Sciences weekly highlights includes analysis of a paper calling for the relaxation of EU regulations that treat advanced therapy medicinal products (ATMPs) as genetically modified organisms (GMOs), details about the Commission’s newly published implementation and preparedness plan for the In Vitro Diagnostic Medical Devices Regulation (IVDR), and news of G7 health ministers agreeing to the Therapeutics and Vaccines Clinical Trials Charter, which aims to improve the efficiency of evidence from vaccine and therapeutic trials.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a quote for Lexis+
* denotes a required field
CONTACT US
